Highlights

  • Second quarter 2026 revenue fell 27% to $52.0 million, as subscription revenue declined $14.8 million on revenue recognition timing.
  • Net loss narrowed to $9.6 million, or $0.59 per share, from $19.5 million, or $1.24 per share, a year earlier.
  • Non-GAAP adjusted EBITDA loss shrank to $1.2 million from $4.7 million as operating expenses dropped 33% year over year.
  • Cash and cash equivalents reached $195.9 million with no debt, and remaining performance obligations stood at $84.3 million.

American Well Corporation (NYSE:AMWL) shares were trading near their 52-week high at USD 13.89 on October 21, 2026, up 5.23%. The digital care platform company finalized contingent consideration from its earlier sale of the APC business in the first half, reported a narrower second quarter loss in a 10-Q filed on August 4, and disclosed that it had no debt.

Based in Boston, Massachusetts, Amwell is a Delaware corporation that was founded in 2006 and describes itself as an enterprise platform and software company enabling hybrid care across in-person, virtual and automated settings. It sells the Amwell Platform on a subscription basis to health systems, health plans and government clients, and adds professional services, Carepoint devices and access to AMG, its affiliated medical group, which delivers clinical visits for a fee. It operates as one reportable segment, and its fiscal year ends December 31.

Revenue Falls 27% While Losses Narrow

Revenue for the three months ended June 30, 2026 was $52.0 million, against $70.9 million a year earlier. Subscription revenue dropped $14.8 million, which the company tied to the timing of revenue recognition with its strategic customers. Other revenue fell $5.8 million, including a $3.0 million decline in professional services and a $2.7 million decline in marketing revenue, while visit revenue rose $1.6 million on a mix weighted toward special program visits. For six months, revenue was $106.9 million, down 22%.

The loss from operations narrowed to $9.6 million from $20.4 million, and net loss was $9.6 million, compared with $19.5 million. The improvement came from cost reductions: research and development fell 43% to $10.4 million, sales and marketing fell 53% to $5.8 million, and general and administrative expense fell 34% to $13.9 million. The company cited headcount reductions, lower stock compensation and reduced consulting spend. Adjusted EBITDA, a non-GAAP measure, was a loss of $1.2 million versus a loss of $4.7 million.

Usage declined. Clients completed about 840,000 visits in the second quarter, down from 1.17 million a year earlier. Management said the six-month decline reflected lower urgent care and behavioral visits tied to customer churn, along with summer seasonality.

Cash, No Debt and Remaining Obligations

Cash and cash equivalents were $195.9 million at June 30, 2026, up from $182.3 million at year end. Operating activities provided $9.7 million of cash in the first six months, compared with a use of $29.8 million a year earlier.

The company reported an accumulated deficit of $2,082.4 million and said it expects to generate operating losses in future periods. It also carries $8.5 million of accrued legal exposure for potential settlements and costs, of which $5.2 million relates to one case, though it expects no pending matter to be material. Transaction price allocated to remaining performance obligations was $84.3 million, down from $85.2 million at year end, with most expected to be satisfied over the next three years.

Severance and strategic transformation costs were $3.8 million for six months, including $3.4 million of accelerated right-of-use amortization after the company abandoned its headquarters lease, and further such costs may follow.

Outlook and Management Priorities

The 10-Q contains no quantitative revenue or earnings guidance. Management said it believes existing cash will meet working capital and capital expenditure needs for at least 12 months from the filing date, while noting that it may need additional equity or debt financing and could be unable to raise it on acceptable terms.

The company expects sales and marketing and general and administrative expenses to stay consistent or relatively flat. Its stated focus is the Amwell Platform, strategic customers and profitability. It also noted that most Medicare telehealth reimbursement flexibilities have been extended through December 31, 2027. The figures above cover the quarter ended June 30, 2026.